(Q33415466)

English

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

Eva Hellström-Lindberg

7

object named as

Eva Hellström-Lindberg

0 references

author name string

Tobias Svensson

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Onima Chowdhury

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hege Garelius

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fryderyk Lorenz

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leonie Saft

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sten-Eirik Jacobsen

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eva Hellström-Lindberg

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Honar Cherif

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

14 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

European Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

93

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

439-445

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

New approaches to the treatment of myelodysplasia.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Role of thrombopoietin in hematopoietic stem cell and progenitor regulation

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Advances in the understanding of congenital amegakaryocytic thrombocytopenia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Persistent malignant stem cells in del(5q) myelodysplasia in remission

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Critical Role of Thrombopoietin in Maintaining Adult Quiescent Hematopoietic Stem Cells

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12383

21 January 2018

Identifiers

10.1111/EJH.12383

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33415466&oldid=1536322577"